共 33 条
[1]
Colwell JA, Is it time to introduce metformin in the US?, Diabetes Care, 16, pp. 653-655, (1993)
[2]
Bloomgarden ZT, The American Diabetes Association Annual Meeting, 1994: Treatment issues for NIDDM, Diabetes Care, 17, pp. 1078-1084, (1994)
[3]
Campbell IW, Management of type 2 diabetes mellitus with special reference to metformin therapy, Diabete Metab, 17, pp. 191-196, (1991)
[4]
Bailey CJ, Metformin: an update, Gen Pharmacol, 24, pp. 1299-1309, (1993)
[5]
Nagi DK, Yudkin JS, Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects, Diabetes Care, 16, pp. 621-629, (1993)
[6]
Campbell IW, Sulphonylureas and metformin: efficacy and inadequacy, New Antidiabetic Drugs, pp. 33-51, (1990)
[7]
Hedges LV, Olkin I, Statistical Methods for Meta‐analysis, (1985)
[8]
Clarke BF, Duncan LJP, Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics, Lancet, 1, pp. 123-126, (1968)
[9]
Clarke BF, Campbell IW, Comparison of metformin and chlorpropamide in non‐obese, maturity‐onset diabetics uncontrolled by diet, Br Med J, 2, pp. 1576-1578, (1977)
[10]
Reduction in HbAl<sub>c</sub> with basal insulin supplement, sulfonylurea, or biguamide therapy in maturity‐onset diabetes: a multicenter study, Diabetes, 34, pp. 793-798, (1985)